NOI for InvivoScribe IGH+IGK Clonality Mega-ABI Assays 75N91026Q00007
Summary
AI-generated · Feb 13, 2026Intent to award a sole-source contract for InvivoScribe IGH+IGK Clonality Mega-ABI Assays to InvivoScribe; this is not a competitive procurement and is conducted under 10 USC 2304(c)(1) and FAR 6.302-1.
InvivoScribe is currently the only provider offering the specific IGH/IGK kit required to support the National Cancer Institute’s molecular laboratories across the Clinical Center protocols.
NOTICE OF INTENT TO AWARD SOLE SOURCE THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. This is a notice of intent to solicit and award a sole source contract under statutory authority 10 USC 2304(c)(1), set forth in Federal Acquisition Regulation 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The Government intends to solicit and award a sole source contract for InvivoScribe IGH+IGK Clonality Mega-ABI Assays to InvivoScribe. InvivoScribe is currently the only provider that carries the specific required IGH/ IGK kit that fits the need of NCI's molecular laboratories servicing the many protocols of the Clinical Center.
From Special Notice posted on Feb 12, 2026Notice history
1-
Special Notice LATEST Posted Feb 12, 2026
Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA